EW Stock Risk & Deep Value Analysis
Edwards Lifesciences Corp
DVR Score
out of 10
What You Need to Know About EW Stock
We analyzed Edwards Lifesciences Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran EW through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
EW Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is that growth in emerging TMTT therapies does not meet high expectations, while the more mature TAVR market eventually plateaus or faces more aggressive competition, making it difficult for EW to sustain its premium valuation and high single-to-low double-digit growth trajectory.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
Q1 2026 included a $123.6M loss on impairment (non-cash, but reduced GAAP EPS).
- ⚠
CEO sales in May 2026, though vesting-related, represent significant value and bear monitoring for future discretionary selling.
Upcoming Risk Events
- 📅
Slower-than-expected adoption or reimbursement for new TMTT therapies
- 📅
Increased competitive pressure from Boston Scientific or Medtronic in TAVR/TMTT
- 📅
Negative clinical trial results for pipeline products
- 📅
Global economic downturn impacting elective cardiovascular procedures
When to Reconsider
- 🚪
Sustained quarterly sales growth deceleration below 5% (constant currency).
- 🚪
A decline in gross margins below 65% for two consecutive quarters.
- 🚪
Significant loss of TAVR or TMTT market share to competitors (e.g., >2% market share decline annually).
Unlock EW Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Edwards Lifesciences represents a quality growth investment in the specialized and expanding structural heart market. Its leadership in TAVR, strong pipeline in TMTT, robust financial health, and consistent execution position it for continued revenue and earnings growth. While a 10x return within 3-5 years is improbable for a company of its scale, it offers a compelling long-term compounder with a strong competitive moat.
Is EW Stock Undervalued?
Unlock the full AI analysis for EW
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
EW Price Targets & Strategy
12-Month Target
$87.00
Bull Case
$97.60
Bear Case
$73.75
Valuation Basis
29x forward P/E applied to the midpoint of revised FY26 adjusted EPS guidance of $3.00
Entry Strategy
Consider dollar-cost averaging in the current range of $80-$82. A dip towards the $75-$78 range would represent a more attractive entry point, historically acting as a support zone.
Exit Strategy
Take partial profit at $95-$97, revisiting the position based on Q2 2026 earnings and TMTT pipeline updates. Set a stop loss around $72.00 (below recent lows if momentum shifts negatively).
Portfolio Allocation
5-7% for moderate risk tolerance due to market leadership and consistent performance within the medical device sector.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is EW Financially Healthy?
Valuation
P/E Ratio
42.73
Forward P/E
29.00
EV/EBITDA
32.00
PEG Ratio
2.08
Price/Book
8.00
Price/Sales
10.00
Profitability
Gross Margin
77.87%
Operating Margin
17.08%
Net Margin
17.39%
Return on Equity
10.59%
Revenue Growth
13.81%
EPS
$1.88
Balance Sheet
Current Ratio
3.72
Quick Ratio
3.02
Debt/Equity
0.06
Other
Beta (Volatility)
0.85
Does EW Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to Expanding
Moat Sources
3 Identified
Edwards' moat is durable due to the high regulatory hurdles, the significant investment required for R&D and clinical trials, and the extensive training and comfort required for physicians to adopt new, life-saving cardiovascular devices. Long-term clinical data is a critical barrier to entry.
Moat Erosion Risks
- •Rapid technological advancements from competitors rendering current devices obsolete
- •Patent expirations or successful legal challenges to IP
- •Changes in healthcare reimbursement policies impacting profitability of devices
EW Competitive Moat Analysis
Sign up to see competitive advantages
EW Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. As a large-cap medical device company, EW typically generates moderate retail investor interest, primarily driven by earnings and product news.
Institutional Sentiment
Positive. Q1 earnings beat and raised guidance typically lead to positive analyst sentiment, though no specific upgrades were provided in the research. The orderly CFO transition is likely viewed positively.
Insider Activity (Form 4)
CEO Bernard J. Zovighian sold 26,198 shares ($2.09M) on May 11, 2026, and 36,351 shares (~$2.83M) in May 2026, both related to equity compensation vesting. Daniel J. Lippis (CVP TAVR) received RSU grants. This activity is routine and not indicative of a negative outlook.
Options Flow
Normal options activity. No unusual put/call ratio or large block trades were identified in the research.
Earnings Intelligence
Next Earnings
Estimated late July 2026 (Q2 2026)
Surprise Probability
Medium-High
Historical Earnings Pattern
Edwards Lifesciences has a history of meeting or exceeding expectations, often leading to modest stock price appreciation on beats, especially if accompanied by guidance raises. Misses or conservative guidance can lead to declines.
Key Metrics to Watch
Competitive Position
Top Competitor
Medtronic (MDT) and Boston Scientific (BSX) are major competitors in structural heart, though EW is a pure-play leader in specific transcatheter valve segments.
Market Share Trend
Gaining slightly. Edwards' global competitive position increased slightly YoY in Q1 2026, primarily due to a competitor's exit in Europe.
Valuation vs Peers
EW typically trades at a premium to its diversified med-tech peers due to its higher growth profile and pure-play exposure to rapidly expanding structural heart markets. Current valuation is likely in line with this historical premium.
Competitive Advantages
- •Strong intellectual property portfolio and regulatory approvals (Intangible Assets)
- •Established clinical data and physician relationships (Switching Costs, Brand Power)
- •Focused R&D in high-growth structural heart segment (Intangible Assets)
- •Specialized manufacturing and technical expertise
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive EW Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Estimated late July 2026)
- •TRIFORMIS surgical tricuspid valve launch (H2 2026)
- •LAAC (Left Atrial Appendage Closure) program introduction (H2 2026)
Medium-Term (6-18 months)
- •Continued global market penetration for TAVR in new patient populations
- •Expansion of TMTT (Transcatheter Mitral & Tricuspid Therapies) market share and new therapy approvals
- •Further expansion into emerging markets for structural heart devices
Long-Term (18+ months)
- •Development and commercialization of next-generation transcatheter valve technologies
- •Potential for new indications for existing therapies and expansion into related cardiovascular segments
- •Sustained innovation maintaining leadership in the structural heart disease treatment paradigm
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for EW?
- ✓
Acceleration in TMTT segment growth and successful clinical outcomes for new therapies.
- ✓
Continued market share gains or stability in the TAVR segment despite competitive pressures.
- ✓
Expansion of gross and operating margins, indicating pricing power and operational efficiency.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Edwards Lifesciences Corp Makes Money
Edwards Lifesciences designs, manufactures, and markets innovative medical technologies for structural heart disease and critical care monitoring. The company makes money by selling advanced medical devices, primarily transcatheter heart valves for conditions like aortic stenosis (TAVR) and mitral/tricuspid regurgitation (TMTT), directly to hospitals and healthcare providers globally. These devices are used in minimally invasive procedures to replace or repair damaged heart valves, offering patients alternatives to open-heart surgery.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Edwards Lifesciences Corp (EW)?
As of May 15, 2026, Edwards Lifesciences Corp has a DVR Score of 6.7 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Edwards Lifesciences Corp?
Edwards Lifesciences Corp's market capitalization is approximately $46.8B..
What is the risk level for EW stock?
Our analysis rates Edwards Lifesciences Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of EW?
Edwards Lifesciences Corp currently has a price-to-earnings (P/E) ratio of 42.7. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Edwards Lifesciences Corp's revenue growing?
Edwards Lifesciences Corp has reported revenue growth of 13.8%. The company is showing strong top-line momentum.
Is EW stock profitable?
Edwards Lifesciences Corp has a profit margin of 17.4%. The company is profitable but margins are modest.
How often is the EW DVR analysis updated?
Our AI-powered analysis of Edwards Lifesciences Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for EW (Edwards Lifesciences Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.